Guangzhou Novaken Pharm Co., Ltd.

广州新济医药股份有限公司

Clinical-stage pharmaceutical company developing modified new drugs using reformulation and drug-delivery technologies on approved APIs. Two core pipeline candidates: a microneedle patch for preoperative sedation and a nasal inhalation therapy for Parkinson's disease, in Phase II trials in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Business changes and acquisitions
• Key long-term agreements
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech